Transfusion medicine
Transfusion transmitted disease
CMV and transfusion

Topic Completed: 1 October 2011

Revised: 5 April 2019

Copyright: 2002-2017,, Inc.

PubMed Search: CMV and transfusion [title] "loattrfree full text"[sb]

Huy Phu Pham, M.D., M.P.H.
Page views in 2018: 11
Page views in 2019 to date: 8
Table of Contents
Definition / general
Cite this page: Pham H. CMV and transfusion . website. Accessed June 25th, 2019.
Definition / general
  • 50 - 85% of U.S. population is CMV+; 50% of U.S. donors are CMV seropositive, compared with 93% in Ghana (Ghana Med J 2006;40:99)
  • Seroconversion rate is 1% per year
  • CMV is almost always latent in immunocompetent adults; CMV virus is latent in leukocytes
  • Leukoreduction reduces risk of CMV transmission
  • Leukoreduced blood products are generally considered equivalent to CMV negative products
  • CMV can cause pneumonitis, hepatitis, retinitis or organ failure in immunocompromised recipients, who should get CMV negative or leukoreduced blood components (Bone Marrow Transplant 2005;36:499, Transfus Med Rev 2005;19:181)
Back to top